Osimertinib: Game-Changing Treatment Non-Small Cell Lung Cancer Lung 5 Mins Read5 In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
Tagrisso the Final ADAURA OS Analysis in Stage IB to IIIA EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 3 Mins Read8 Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
